An Clinical Study of NKG2D-CAR-NK Cells for the Treatment of Refractory Recurrent Multiple Myeloma - Trial NCT06379451

Timeline & Enrollment

Primary Outcome

Incidence of Dose Limiting Toxicity (DLTs),Treatment Emergent Adverse Events (TEAEs)

Summary

Multiple myeloma (MM) is a malignant disease characterized by the abnormal proliferation of
 clonal plasma cells. However, multiple myeloma remains an incurable disease and requires the
 exploration of more effective treatment methods to improve the efficacy of relapsed
 refractory multiple myeloma and prolong survival time.Currently, clinical application of
 CAR-T is mostly based on autologous T cell preparation, while relapsed/refractory AML
 patients have undergone multiple chemotherapy treatments, resulting in impaired self-T cell
 function, which affects the efficacy and prognosis of CAR-T therapy. Therefore, it is
 necessary to find new alternative treatments. NK cells are important immune cells in the body
 and are an important component of innate immunity. Compared with CAR-T cell therapy, CAR-NK
 cells have unique advantages in adoptive cell therapy. NKG2D receptor is an activating
 receptor expressed on NK cells, which can recognize NKG2D ligands (NKG2DL) expressed on tumor
 cells, activating NK cell killing activity through NKG2D-NKG2DL interaction. Therefore, the
 investigators plan to treat relapsed multiple myeloma by infusing NKG2D-CAR-NK cells to
 evaluate its efficacy and safety.

ICD-10 Classifications